Intellia Therapeutics on April 27, 2026, began a rolling submission of a biologics license application to the Food and Drug Administration for lonvo-z, its hereditary angioedema treatment that was formerly known as NTLA-2002. On the same day, the company said it had positive topline results from the Phase 3 HAELO trial.
The drug is designed as a one-time outpatient treatment and uses in vivo CRISPR gene editing to inactivate the kallikrein B1 gene, with the goal of permanently lowering kallikrein and bradykinin levels. If approved, John Leonard said lonvo-z would become the world’s first in vivo CRISPR-based gene editing therapy.
Intellia said HAELO met its primary endpoint and all key secondary endpoints. During the six-month primary observation period, a one-time dose of lonvo-z left most patients free of both hereditary angioedema attacks and the need for ongoing therapy, according to the company. Leonard said the results reinforce Intellia’s view that the treatment could change how the disease is managed and spare many patients from attacks and chronic medication with a single dose.
The filing matters because it moves lonvo-z from clinical testing toward a possible regulatory review at a time when gene editing companies are trying to prove their therapies can work outside rare one-off successes. Intellia said it expects to complete the BLA submission in the second half of 2026, and if the FDA accepts the filing, the agency is expected to decide whether to grant priority review and set a target action date.
There is still a gap between a strong trial readout and a commercial launch. Intellia has already collected five notable regulatory designations for lonvo-z, including Orphan Drug and RMAT status from the FDA, Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency, Priority Medicines designation from the European Medicines Agency and Orphan Drug Designation from the European Commission. The company also took part in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot, a sign that manufacturing readiness will be part of the next phase of scrutiny. If the treatment clears the agency, Intellia plans a first-half 2027 launch.
For now, the story is simple: a single-dose CRISPR therapy for hereditary angioedema has reached the FDA filing stage with data strong enough to push the program closer to a potential first-of-its-kind approval.